{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:36:29Z","timestamp":1768462589676,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00228-023-03478-4","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T11:04:46Z","timestamp":1679569486000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictive factors associated with pemetrexed acute toxicity"],"prefix":"10.1007","volume":"79","author":[{"given":"Mathilde","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Jouinot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascaline","family":"Boudou-Rouquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Seif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Villeminey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Thomas-Schoemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"3478_CR1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. J Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol"},{"key":"3478_CR2","unstructured":"ALIMTA: Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alimta. Accessed 15 Mar 2022"},{"key":"3478_CR3","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"3478_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30\u201335. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.022","journal-title":"Lung Cancer"},{"issue":"12","key":"3478_CR5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Piet B, Derijks HJ et al (2021) Mechanisms, management and prevention of pemetrexed-related toxicity. Drug Saf 44(12):1271\u20131281. https:\/\/doi.org\/10.1007\/s40264-021-01135-2","journal-title":"Drug Saf"},{"key":"3478_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6:546\u2013558. https:\/\/doi.org\/10.1038\/nrc1887","journal-title":"Nat Rev Cancer"},{"key":"3478_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2133\/dmpk.DMPK-13-RG-042","volume":"29","author":"T Kurata","year":"2014","unstructured":"Kurata T, Iwamoto T, Kawahara Y, Okuda M (2014) Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 29:148\u2013153. https:\/\/doi.org\/10.2133\/dmpk.DMPK-13-RG-042","journal-title":"Drug Metab Pharmacokinet"},{"key":"3478_CR8","doi-asserted-by":"publisher","unstructured":"Kawazoe H, Yano A, Ishida Y et al (2017) Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study. PLoS ONE 12:e0171066. https:\/\/doi.org\/10.1371\/journal.pone.0171066","DOI":"10.1371\/journal.pone.0171066"},{"key":"3478_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11096-019-00958-5","volume":"42","author":"X Wang","year":"2020","unstructured":"Wang X, Song Y, Wang J et al (2020) Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis. Int J Clin Pharm 42:23\u201330. https:\/\/doi.org\/10.1007\/s11096-019-00958-5","journal-title":"Int J Clin Pharm"},{"key":"3478_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1114248","journal-title":"N Engl J Med"},{"key":"3478_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/00365510410003723","volume":"64","author":"A Larsson","year":"2004","unstructured":"Larsson A, Malm J, Grubb A, Hansson LO (2004) Calculation of glomerular filtration rate expressed in mL\/min from plasma cystatin C values in mg\/L. Scand J Clin Lab Invest 64:25\u201330. https:\/\/doi.org\/10.1080\/00365510410003723","journal-title":"Scand J Clin Lab Invest"},{"key":"3478_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2022.02.007","volume":"166","author":"F Slimano","year":"2022","unstructured":"Slimano F, Le Bozec A, Cransac A et al (2022) Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: the prospective IPPEM study. Lung Cancer 166:114\u2013121. https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.007","journal-title":"Lung Cancer"},{"key":"3478_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"Griesinger F, Korol EE, Kayaniyil S et al (2019) Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 135:196\u2013204. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.010","journal-title":"Lung Cancer"},{"key":"3478_CR14","doi-asserted-by":"publisher","unstructured":"Araki R, Keira T, Masuda Y et al (2018) Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed\/carboplatin combination chemotherapy. J Clin Pharm Ther 12788. https:\/\/doi.org\/10.1111\/jcpt.12788","DOI":"10.1111\/jcpt.12788"},{"key":"3478_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1124\/dmd.116.070722","volume":"44","author":"K Ikemura","year":"2016","unstructured":"Ikemura K, Hamada Y, Kaya C et al (2016) Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral human organic anion transporter 3. Drug Metab Dispos 44:1543\u20131549. https:\/\/doi.org\/10.1124\/dmd.116.070722","journal-title":"Drug Metab Dispos"},{"key":"3478_CR16","unstructured":"Farrell B, Pottie K, Thompson W et al (2017) Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician 63(5):354\u2013364"},{"key":"3478_CR17","doi-asserted-by":"publisher","unstructured":"Bridoux M, Simon N, Turpin A (2022) Proton pump inhibitors and cancer: current state of play. Front Pharmacol 13:798272. https:\/\/doi.org\/10.3389\/fphar.2022.798272","DOI":"10.3389\/fphar.2022.798272"},{"key":"3478_CR18","doi-asserted-by":"crossref","unstructured":"Bretagne M, Jouinot A, Durand JP et al (2017) Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemother Pharmacol 9","DOI":"10.1093\/annonc\/mdw390.38"},{"key":"3478_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.kint.2021.12.010","volume":"101","author":"Costa e Silva VT, Gil LA, Inker LA,","year":"2022","unstructured":"Costa e Silva VT, Gil LA, Inker LA et al (2022) A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int 101:607\u2013614. https:\/\/doi.org\/10.1016\/j.kint.2021.12.010","journal-title":"Kidney Int"},{"key":"3478_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chest.2019.04.115","volume":"156","author":"M Yang","year":"2019","unstructured":"Yang M, Shen Y, Tan L, Li W (2019) Prognostic value of sarcopenia in lung cancer. Chest 156:101\u2013111. https:\/\/doi.org\/10.1016\/j.chest.2019.04.115","journal-title":"Chest"},{"key":"3478_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2407-10-50","volume":"10","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Michel Ortega RM, Villanueva-Rodr\u00edguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50. https:\/\/doi.org\/10.1186\/1471-2407-10-50","journal-title":"BMC Cancer"},{"key":"3478_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","volume":"161","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Yokoi T et al (2021) Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer 161:26\u201333. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.015","journal-title":"Lung Cancer"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03478-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03478-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T08:06:31Z","timestamp":1681718791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03478-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3478"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03478-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the local Ethics Committee (N\u00b022\u20137125) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}